Aims: To determine the ramifications of empagliflozin on adiposity indices among sufferers with type 2 diabetes mellitus. all indices of adiposity in the EMPA-treated groupings weighed against placebo in both research cohorts (Body 1(a) to (d)). The altered mean (95%…